Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II R-CVP chemotherapy in non-conjunctival ocular adnexal MALT lymphoma
KCT0003048Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, vincristine, prednisolone in Orbital Lymphoma (OL), sponsored by Roche. Started Nov 2011; status: active, not recruiting.
02
Drugs
rituximabcyclophosphamidevincristineprednisolone
03
Conditions
Orbital Lymphoma (OL)
Beyond the preview
Go deeper on KCT0003048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003048.